AlzeCure Pharma: AlzeCure Gets Abstract Accepted on Potential Neuroprotective Effects of NeuroRestore ACD856

STOCKHOLM, SWEDEN / ACCESSWIRE / August 30, 2022 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6)AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule

Related Keywords

Sweden ,Athens ,Attikír ,Greece ,Stockholm ,Swedish ,Pontus Forsell ,Sanja Juric ,Alzecure Pharma ,Johan Sandin ,Dnr Johan Sandin ,Cristina Parrado ,Head Of Research ,International Society For Molecular Neurodegeneration ,International Society ,Molecular Neurodegeneration ,Brain Derived Neurotrophic Factor ,Nasdaq First North Premier Growth Market ,Nerve Growth Factor ,Alzecure ,Dharma ,Jets ,Abstract ,Accepted ,Potential ,Neuroprotective ,Effects ,Neurorestore ,Cd856 ,